Nona Biosciences, a leading global biotechnology company, has once again demonstrated its expertise in pharmacological evaluation, as evidenced by its latest supplemental agreements with Kelun Biotech. The company's ability to provide comprehensive "Idea to IND" (I to ITM) solutions, including thorough pharmacological assessments, has been pivotal in fostering successful partnerships and driving the development of transformative next-generation biotherapeutics.

At the heart of Nona Biosciences' antibody pharmacological evaluation capabilities is its integrated antibody discovery platform, which leverages the company's proprietary Harbour Mice® technology. This versatile platform generates fully human monoclonal antibodies in both the classical two light and two heavy chain (H2L2) format and the heavy chain-only (HCAb) format. By combining the Harbour Mice® platform with its advanced single B cell screening system, Nona Biosciences is able to identify and engineer a diverse array of antibody-based therapeutics, including antibody-drug conjugates (ADCs), bispecific antibodies, and other innovative modalities.

The latest supplemental agreements between Nona Biosciences and Kelun Biotech underscore the value of the company's pharmacological evaluation expertise. Under these agreements, Nona Biosciences has licensed two ADC products (Product 1 and Product 2) to Kelun Biotech, which will then have the right to sublicense them to a third party. In return, Nona Biosciences is entitled to receive a substantial share of the upfront payments, milestone payments, and tiered royalties from the commercialization of these products.

This arrangement highlights the trust and confidence that Kelun Biotech has placed in Nona Biosciences' ability to rigorously evaluate the pharmacological properties of the ADC products. Through its comprehensive I to ITM solutions, Nona Biosciences has not only contributed to the discovery and development of these innovative therapies but has also ensured their readiness for further clinical advancement and commercialization.

"Our collaboration with Kelun Biotech is a testament to the strength of our pharmacological evaluation capabilities and the value we bring to our partners," said Dr. Jingsong Wang, Founder, Chairman, and CEO of HBM Holdings Limited, the parent company of Nona Biosciences. "By leveraging our Harbour Mice® platform and the expertise of our talented team, we are able to generate differentiated therapeutic molecules that meet the highest standards of safety and efficacy, ultimately benefiting patients worldwide."

As Nona Biosciences continues to forge new partnerships and expand its global reach, the company's commitment to pharmacological evaluation remains a key differentiator. By seamlessly integrating this critical step into its comprehensive I to ITM solutions, Nona Biosciences is empowering its partners to navigate the complex landscape of biotherapeutic development with confidence and success.